| Project/Area Number |
24591343
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Nihon University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMAGUCHI Suguru 日本大学, 医学部, 助教 (70451614)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
OKAMOTO Mayumi 日本大学, 医学部, 講師 (80349993)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | グルカゴン / インクレチン / スルホニル尿素受容体 / DPP-4阻害薬 / メトホルミン / 膵α細胞 / 膵ランゲルハンス島 / インスリン / スルホニル尿素薬 |
|---|
| Outline of Final Research Achievements |
Increased glucagon secretion is an essential pathogenic abnormality found in type 2 diabetes patients. In this study, we have conducted several experiments aiming to elucidate mechanisms of glucagon secretion and to apply the results for analyzing pathogenesis of type 2 diabetes in humans. We found that modulation of the sulfonylurea receptor signaling by zinc and GLP-1 could be involved in glucagon secretion, providing insights for further analysis on its mechanisms. We have also conducted a clinical study in which type 2 diabetes patients on insulin monotherapy were treated either with sitagliptin, a DPP-4 inhibitor, or metformin, a biguanide compound. We have demonstrated that sitagliptin improved glycemic control by reducing glucagon secretion. In parallel, we have compared glucagon immunoassays, and found that a newly developed glucagon ELISA revealed more dynamic changes in glucagon after a meal challenge test.
|
